Corticosteroids in the management of central nervous system tumours

Open Access
Publisher Website
Google Scholar
Abstract
Kofman et al first reported the beneficial role of glucocorticoids in managing brain tumours in 1957 after prednisolone was given to 20 adults with brain metastases.4 These drugs are now routinely administered to children with symptomatic CNS tumours.5 The rationale for their use is to improve neurological function by reducing associated brain or spinal oedema, although the mechanism by which this occurs is unresolved.6 7 Glucocorticoids increase membrane stability and thereby correct flux of sodium, potassium, and water across the cell membrane.8 There is evidence that they may reduce vascular permeability.9 10